LithoVue Elite system's real-time IRP monitoring may enhance flexible ureteroscopy for larger stones, offering data-driven pressure management. CVAC 2.0 ureteroscope demonstrates safety and efficacy ...
Kevin C. Zorn, MD, FRCSC, FACS, outlines notable advances in the management of benign prostatic hyperplasia over the past year. In a recent interview with Urology Times®, Kevin C. Zorn, MD, FRCSC, ...
The PROSTOX ultra test predicts late genitourinary toxicity risks in localized prostate cancer patients undergoing stereotactic body radiotherapy. Genomic testing aids in refining treatment intensity ...
Non-muscle invasive bladder cancer treatments have expanded beyond BCG, offering alternatives to radical cystectomy with flexible dosing and scheduling. Muscle-invasive bladder cancer management is ...
Scott Tagawa, MD, provides an overview of key findings from the PSMAddition study, evaluating 177Lu-PSMA-617 combined with ADT and ARPI in mHSPC. Data from the phase 3 PSMAddition trial (NCT04720157) ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking ...
Panelists discuss current FDA-approved treatments for BCG-unresponsive carcinoma in situ, noting varying response rates among pembrolizumab, nadofaragene, and BCG combined with IL-15 superagonist, ...
Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...
“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” says Dean Elterman, MD. “We're now entering an era of new types of technologies to treat BPH in a ...
UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback